Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VenBom: Bomedemstat and Venetoclax in Relapsed/Refractory AML
NCT05597306Phase 1Recruiting
- Start
- Nov 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bomedemstat in acute myeloid leukemia (AML) (2 cohorts). Primary endpoints: Incidence of Treatment-Emergent Toxicity at 72 weeks and Recommended Phase 2 Dose at 72 weeks. Started Nov 2022; status: recruiting.
02
Drugs
bomedemstat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05597306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05597306.